ptx_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2010
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Maryland
|
|
001-14494
|
|
33-0724736
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
| |
|
|
|
33219 Forest West Street
Magnolia, TX
|
|
77354
|
| |
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (832) 934-1825
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 30, 2010, the Board of Directors of Pernix Therapeutics Holdings, Inc. (the “Company”) unanimously approved a change in the office held by Michael Venters from Executive Vice President of Operations to Vice President of Corporate Development. Following Mr. Venters’ appointment as Vice President of Corporate Development of the Company, the position of Executive Vice President of Operations was eliminated.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
PERNIX THERAPEUTICS HOLDINGS, INC. |
|
| |
|
|
|
|
Dated: September 30, 2010
|
By:
|
/s/ Tracy S. Clifford |
|
| |
|
Tracy S. Clifford |
|
| |
|
Chief Financial Officer |
|
| |
|
|
|